Advanced Viral Research Corp. Receives Approval in Argentina for Human Clinical Studies With Antiviral &uot;Substance R&uot;.Health/Medical &Biotechnology Writers YONKERS, N.Y.--(BW HealthWire)--Feb. 18, 2000 Research Shows Drug Inhibits Production of CCR5, Stimulates the Immune System &Interferes with Viral Replication to Fight AIDS, HPV HPV human papillomavirus. HPV abbr. human papilloma virus Human papilloma virus (HPV) &Other Diseases Advanced Viral Research Corp. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :ADVR ADVR Association of Directors of Volunteer Resources (Canada) ) today announced that Substance R, its non-toxic peptide nucleic acid (PNA) immunomodulator, has received formal approval for Phase I human clinical studies in Argentina. Substance R (Panar 097, Reticulose(TM)), is a non-toxic peptide nucleic acid being developed by the company as a broad spectrum antiviral drug. The drug shows promise for the treatment of viral infections such as AIDS and Human Papilloma Virus human papilloma virus n. Abbr. HPV A DNA virus of the genus Papillomavirus, certain types of which cause cutaneous and genital warts in humans, including condyloma acuminatum. (HPV), and autoimmune diseases like rheumatoid arthritis and diabetes mellitus. Peptide nucleic acids are stable analogues of genes and have applications as genomics. Advanced Viral Research Corp. laboratory studies have shown that Substance R inhibits the production of both the CCR5 and CXCR4 chemokine receptors, the key cellular co-receptors for the human immunodeficiency virus human immunodeficiency virus n. HIV. Human immunodeficiency virus (HIV) A transmissible retrovirus that causes AIDS in humans. (HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. ). &uot;The approval of human trials in Argentina is a very important step on the road to making Substance R available for clinical use worldwide,&uot; said Shalom Z. Hirschman, M.D., President and Chief Executive Officer of Advanced Viral Research Corp. &uot;Working with our scientific colleagues in Argentina, we have successfully laid the groundwork to move our application through ANMAT ANMAT Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (Argentina) (the Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica medica (māˑ·dē·k -- National Administration for Drug, Food and Medical Technology), so that we may market Substance R in their country, helping to alleviate the suffering of people with a variety of debilitating de·bil·i·tat·ing adj. Causing a loss of strength or energy. Debilitating Weakening, or reducing the strength of. Mentioned in: Stress Reduction diseases. I am especially gratified that the clinical approvals are progressing as planned in Argentina while we prepare our applications to the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. in the United States,&uot; Dr. Hirschman stated. Clinical trials in patients with AIDS and HPV (the cause of genital warts and a critical factor in the development of cervical cancer) are planned in Argentina. The approval for human clinical tests in Argentina also paves the way for future study of the therapeutic effects of Substance R in other important diseases, such as rheumatoid arthritis and diabetes mellitus. Substance R is a second-generation therapeutic. Its predecessor was developed in the early 1900s. Using modern medical technology, scientists at The Advanced Viral Research Institute have refined the PNA preparation and pharmaceutical production, making today's Substance R a truly novel drug. About The Advanced Viral Research Institute Advanced Viral Research Corp.'s foundation begins with a dedication to scientific research and cutting-edge innovation. In that spirit, the company created The Advanced Viral Research Institute to foster individual scientific inquiry and creativity. Here, a respected team of molecular biologists, immunologists and other scientists conduct biomedical research in an academically oriented environment. Recent successes include identifying Substance R's mechanism of action, which will help with the company's planned Investigational New Drug (IND) application to the FDA. The Advanced Viral Research Institute also is developing other PNA-based therapeutics. About Advanced Viral Research Corp. Advanced Viral Research Corp., based in Yonkers, New York Yonkers is the fourth largest city in the State of New York (it falls behind New York City, Buffalo, and Rochester), and the largest city in Westchester County, with a population of 196,086 (according to the 2000 census). , is a biopharmaceutical firm committed to researching, developing and bringing to market new, effective therapies for viral and other diseases, which will lead to the alleviation of human suffering and diseases worldwide. Its flagship drug, Substance R (Reticulose(TM)), is a non-toxic immunomodulator that has been shown to have beneficial therapeutic effects against viral diseases such as AIDS. Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by ADVR. Substance R (Reticulose(TM)) is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion